PolyPid Ltd.

PYPD Healthcare Biotechnology

In the quarter to June 2026, EPS grew 55.1%, free cash flow fell 65.0% and total debt fell 88.4%, each against the same quarter a year earlier.

4.75 0.15 −3.06%
Market cap
$99.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
10.75 5.57 2.18 10.62 16.41 4.31 1.66 0.83 1.31 1.97
Net Debt/EBITDA
1.75 1.32 0.42 1.53 1.78 0.78 0.04 (0.23) 0.32 0.39
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 1.99 (4.95) 0.97 0.09
ROE
22.84% 96.48% (6.95%) 8.16% 577.80% (78.36%) (189.32%) (1,278.60%) (1,038.73%) (366.29%)
ROA
(66.32%) (614.88%) 35.09% (28.63%) (78.31%) (70.95%) (112.69%) (115.45%) (142.99%) (143.79%)
ROIC
0.00% 0.00% 0.00% 0.00% (58.83%) (802.55%) (562.36%) (533.88%) 0.00% 0.00%
Return on Tangible Assets
(80.45%) (323.32%) 56.17% (22.32%) (85.47%) (120.02%) (265.70%) (372.77%) (291.18%) (271.57%)
Average Days of Receivables
0.00 0.00 0.00 0.00 0.00 — — — — —
Free Cash Flow per Share
(0.73) (0.93) (1,056.26) (975.24) (70.13) (56.21) (55.72) (12.41) (3.73) (1.72)
Book value per Share
0.76 (2.16) (4,369.52) 998.98 228.07 57.68 9.00 (1.49) 1.30 0.67
Free Cash Flow
(9.73) (12.31) (19.75) (18.24) (22.38) (35.04) (36.08) (17.43) (22.04) (28.09)
Other line items

Show all line items

Columns are period end dates